Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные)

Автор: Авдеева А.С., Кусевич Д.А.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Форум молодых ученых

Статья в выпуске: 3 т.55, 2017 года.

Бесплатный доступ

Ревматоидный артрит (РА) является наиболее частым и тяжелым хроническим воспалительным заболеванием суставов, приводящим к ранней инвалидизации и сокращению продолжительности жизни пациентов. В ряде работ продемонстрировано, что краткосрочный и долгосрочный прогноз заболевания гораздо более благоприятен при достижении ремиссии на ранних стадиях болезни, однако эффективность того или иного лекарственного препарата широко варьирует у разных пациентов, что связано с гетерогенностью самого заболевания и рядом других причин. В связи с этим по-прежнему актуальной остается проблема поиска биомаркеров, позволяющих осуществлять персонифицированный выбор схемы лечения в каждом конкретном случае. Одним из эффективных и безопасных препаратов, применяемых в терапии РА, является ритуксимаб (РТМ), представляющий собой химерные моноклональные антитела к мембранному CD20 антигену В-клеток, вызывающие деплецию различных субпопуляций В-лимфоцитов. По сравнению с другими генно-инженерными биологическими препаратами, РТМ отличается длительной эффективностью одного курса терапии, сохраняющейся в течение 6 мес и более. В настоящее время в литературе представлено большое количество данных, посвященных роли клеточных и молекулярных биомаркеров в прогнозировании эффективности терапии РТМ при РА, часть из которых рассмотрены в данном обзоре.

Еще

Ревматоидный артрит, активность заболевания, ритуксимаб, эффективность терапии, клеточные и молекулярные биомаркеры

Короткий адрес: https://sciup.org/14945823

IDR: 14945823   |   DOI: 10.14412/1995-4484-2017-295-303

Список литературы Роль лабораторных биомаркеров в прогнозировании эффективности терапии ритуксимабом при ревматоидном артрите (новые данные)

  • Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331
  • Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012
  • Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75 DOI: 10.1136/ard.2009.126532
  • Rantalaiho V, Korpela M, Laasonen L, et al; FIN-RACo Trial Group. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12:R122 DOI: 10.1186/ar3060
  • Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347-56 DOI: 10.1002/art.10083
  • Viatte S, Plant D, Bowes J, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis. 2012;71:1984-990 DOI: 10.1136/annrheumdis-2011-201225
  • De Rooy D, Yeremenko NG, Wilson AG et al. Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2013;72:769- DOI: 10.1136/annrheumdis-2012-202184
  • Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20. Blood. 1994;83:435-45.
  • Emery P, Fleishmann R, Filipowicz-Sosnowska A, et al; for the DANCER Study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthritis Rheum. 2006;54:1390-400 DOI: 10.1002/art.21778
  • Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806 DOI: 10.1002/art.22025
  • Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of Rituximab: a randomized, placebo-controlled trial in patients who are biologically naive with active rheumatoid arthritis and anadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX inadequate responders (SERENA). Ann Rheum Dis. 2010;69:1629-35 DOI: 10.1136/ard.2009.119933
  • Rubbert-Roth A, Tak PP, Zebrini C, et al. Efficacy and safety of various repeat treatment dosing regimes in Rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). Rheumatology. 2010;49:1683-93 DOI: 10.1093/rheumatology/keq116
  • Gabay C, Chatzidionysiou K, Nasonov E, et al. Effectiveness of different DMARD co-therapy in Rituximab-treated rheumatoid arthritis (RA) patients -results of a one-year follow up study from CERRERA collaboration. Ann Rheum Dis. 2010;69 Suppl 3:68.
  • Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with Rituximab in the Autoimmunity and Rituximab (AIR) registry. Arthritis Rheum. 2010;62:2625-32 DOI: 10.1002/art.27555
  • Keystone E, Fleishmann R, Emery P, et al. Sustained efficacy is achieved with repeat courses of rituxumab in patients with rheumatoid arthritis with inadequate response to one or more TNF inhibitors. Rheumatology. 2010;49 Suppl 1:i98 (173).
  • Cohen S, Keystone E, Genovese M, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69:1158-61 DOI: 10.1136/ard.2009.119222
  • Leandro M, Cambridge G, Ehrenstein M, Edwards JCW. Reconstitution of peripheral blood B cell after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613-20 DOI: 10.1002/art.21617
  • Trouvin A-P, Jacquot S, Grigioni S, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exper Immunol. 2014;180:11-8 DOI: 10.1111/cei.12481
  • Sellam J, Abbed K, Rouanet S, et al. Pre-therapeutic decrease frequency of memory B cells is predictive of response to a first course of Rituximab in rheumatoid arthritis patients with inadequate response or intolerance to anti-TNF: data from the SMART trial. Ann Rheum Dis. 2010;69 Suppl 3:490.
  • Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum. 2010;62:1273-9 DOI: 10.1002/art.27359
  • Roll P, Dorner T, Tony H-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58:1566-75 DOI: 10.1002/art.23473
  • Müller B, Aeberli D, Eggli S, et al. Class-switched B cells display response to therapeutic B-cell epletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R62 DOI: 10.1186/ar2686
  • Stradner M, Dejaco C, Brickmann K, et al. A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Res Ther. 2016;18:190 DOI: 10.1186/s13075-016-1091-1
  • Brezinschek HP, Rainer F, Brickmann K, et al. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 2012;14(4):R161 DOI: 10.1186/ar3901
  • Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:2783-90 DOI: 10.1002/art.38107
  • Lavielle M, Mulleman D, Goupille P, et al. Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. Arthritis Res Ther. 2016;18:253 DOI: 10.1186/s13075-016-1152-5
  • Ferraccioli G, Tolusso B, Pallavicini F, et al. Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive rheumatoid arthritis patients. Arthritis Rheum. 2010;62 Suppl 10:1098.
  • Dass S, Rawstron A, Vital E, et al. High sensitivity B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:2993-9 DOI: 10.1002/art.23902
  • Vital E, Dass S, Buch M. A randomized double-blind placebo controlled trial on the effects of increased dose Rituximab in patients with initial incomplete depletion -the extended treatment with Rituximab in rheumatoid arthritis (EXTRA) trial. Ann Rheum Dis. 2010;69 Suppl 3:147.
  • Isaacs J, Olech E, Tak P, et al. Autoantibody-positive RA patients have enhanced clinical response to rituximab when compared with seronegative patients. Ann Rheum Dis. 2009;68 Suppl 3:442.
  • Khan A, Mahmud T, Hammond T, et al. Rituximab (RTX) is more effective in active sero-positive RA than sero-negative RA. Arthritis Rheum. 2010;62 Suppl 10:1830.
  • Mariette X, Kivitz A, Isaacs J, et al. Effectiveness of Rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease charaxteristics associated with poor outcomes. Arthritis Rheum. 2009;60 Suppl:631.
  • Александрова ЕН, Авдеева АС, Лукина ГВ и др. Клиникоиммунологические эффекты анти-В-клеточной терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(1):14-21
  • Tak P, Rigby W, Rubbert-Roth A. Inhibition ofjoint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46 DOI: 10.1136/ard.2010.137703
  • Авдеева АС, Александрова ЕН, Новиков АА и др. Иммунологические предикторы эффекта анти-В-клеточной терапии при ревматоидном артрите. Клиническая лабораторная диагностика. 2014;(3):48-52
  • Lindenberg L, Spengler L, Bang H, et al. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17:206 DOI: 10.1186/s13075-015-0717-z
  • Sellam J, Riviere E, Courties A, et al. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18:294 DOI: 10.1186/s13075-016-1190-z
  • Sellam J, Marion-Thore S, Dumont F, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheum. 2014;66(8):2015-25 DOI: 10.1002/art.38671
  • Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499-505 DOI: 10.1136/annrheumdis-2013-203923
  • Choi IY, Gerlag DM, Holzinger D, et al. From Synovial Tissue to Peripheral Blood: Myeloid Related Protein 8/14 Is a Sensitive Biomarker for Effective Treatment in Early Drug Development in Patients with Rheumatoid Arthritis. PLoS ONE. 2014;9(8):e106253 DOI: 10.1371/journal.pone.0106253
  • Nair SC, Welsing PMJ, Choi IYK, et al. A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. PLoS ONE. 2016;11(3):e0152362 DOI: 10.1371/journal.pone.0152362
  • Couderc M, Mathieu S, Pereira B, et al. Predictive factors of rit-uximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res. 2013;65:648-52 DOI: 10.1002/acr.21865
  • Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis. 2013;73:716-21 DOI: 10.1136/annrheumdis-2012-202435
  • Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fc(gamma) receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012;71:875-7 DOI: 10.1136/annrheumdis-2011-200337
  • Kastbom A, Coster L, Arlestig L, et al. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open. 2012;2:e001524 DOI: 10.1136/bmjopen-2012-001524
  • Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62:3607-14 DOI: 10.1002/art.27702
  • Raterman HG, Vosslamber S, De RS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14:R95 DOI: 10.1186/ar3819
  • Edwards J, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81 DOI: 10.1056/NEJMoa032534
  • Higashida J, Wun T, Schmidt S. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.
  • Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67:917-25 DOI: 10.1136/ard.2007.080960
  • Narvaez J, Torne C, Ruiz J, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARD. Arthritis Rheum. 2010;62 Suppl 10: 1118.
  • Peluso G, Fuustin F, Gremese E, et al. B-cell depletion in rheumatoid arthritis: searching for serologic and clinical baseline factors that could predict long-term efficacy. Ann Rheum Dis. 2010;69 Suppl 3:683.
  • Boire G, Gosette P, Combe B, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients witch recent-onset polyarthritis. Arthritis Res Ther. 2005;7:R529-603 DOI: 10.1186/ar1719
  • Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthr Res Ther. 2004;6:R142-50 DOI: 10.1186/ar1149
  • Engel P, Gomez-Puerta J, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev. 2011;63:127-56 DOI: 10.1124/pr.109.002006
  • Lund F. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol. 2008;20:332-8 DOI: 10.1016/j.coi.2008.03.003
  • Manjarrez-Orduno N, Quach T, Sanz I, et al. B cells and immunological tolerance. J Invest Dermatol. 2009;129:278-88 DOI: 10.1038/jid.2008.240
  • Blom M, Wenink MH, Huijbens RJF, et al. Altered circulating cytokine pattern after administration of rituximab is correlated with response to therapy in rheumatoid arthritis. Arthritis Rheum. 2008;26 Suppl:764.
  • Fabre S, Gvisset C, Tatem L, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol. 2008;155:395-402 DOI: 10.1111/j.1365-2249.2008.03804.x
  • Thurling R, Boumans M, Vos K, et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to Rituximab treatment in rheumatoid arthritis. Arthritis Rheum. 2009;60 Suppl:630.
  • Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103-10 DOI: 10.1038/nri2692
  • Theoharides TC, Petra AI, Taracanova A, et al. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther. 2015;354(1):24-31 DOI: 10.1124/jpet.114.222505
  • Millar NL, Murrell GAC, McInnes IB. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology. 2013;52(5):769-79 DOI: 10.1093/rheumatology/kes409
  • Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90 DOI: 10.1016/j.immuni.2005.09.015
  • Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-a dependent effects in synovial fibroblasts. Int J Mol Med. 2012;29(4):530-40 DOI: 10.3892/ijmm.2012.883
  • Malcolm J, Awang RA, Oliver-Bell J, et al. IL-33 exacerbates periodontal disease through induction of RANKL. J Dent Res. 2015;94(7):968-75 DOI: 10.1177/0022034515577815
  • Lee E-J, So MW, Hong S, et al. Interleukin-33 acts as a transcriptional repressor and extracellular Cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine. 2016;77:35-43 DOI: 10.1016/j.cyto.2015.10.005
  • Xiangyang Z, Lutian Y, Lin Z, et al. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine. 2012;58(1):6-9 DOI: 10.1016/j.cyto.2011.12.010
  • Komai-Koma M, Gilchrist DS, McKenzie ANJ, et al. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol. 2011 Feb 15;186(4):2584-91 DOI: 10.4049/jimmunol.1002103
  • Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R39 DOI: 10.1186/ar2645
  • Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16:713-7 DOI: 10.1038/nm.2150
  • Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol. 1998;160:1427-35.
  • Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteom Res. 2002;1:495-9 DOI: 10.1021/pr025531w
  • Van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67:1750-8 DOI: 10.1136/ard.2007.077800
  • Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005;105:2955-62 DOI: 10.1182/blood-2004-07-2520
  • Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-8 DOI: 10.1182/blood-2004-020446
  • Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266-73 DOI: 10.1001/jama.2010.375
  • Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974-80 DOI: 10.1136/annrheumdis-2011-200598
  • Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2011;70:2075-81 DOI: 10.1136/ard.2011.152496
  • Cuppen B, Welsing P, Sprengers JJ, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 2016;55:826-39 DOI: 10.1093/rheumatology/kev421
  • Daien CI, Fabre S, Rittore C, et al. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine. 2012;79:471-5 DOI: 10.1016/j.jbspin.2011.10.007
  • Fabris M, de Vita S, Blasone N, et al. Serum levels of antiCCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Autoimmun Highlights. 2010;1:87-94 DOI: 10.1007/s13317-010-0013-5
  • Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2012;64:1108-15.
  • Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63:933-8 DOI: 10.1002/art.30233
  • Choi YK, Herenius MJ, Wijbrandts CA, et al. MRP8/14 serum complexes as predictor of response to biological treatments in rheumatoid arthritis. Ann Rheum Dis. 2013;72:499-505.
  • Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36-49 DOI: 10.1038/nri3581
  • Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66:1008-14 DOI: 10.1136/ard.2006.063412
  • Насонов ЕЛ, Лукина ГВ, Сигидин ЯАидр. Применение моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите в России (Предварительные результаты Российского регистра). Терапевтический архив. 2008;80(8):57-62
Еще
Статья научная